1. Home
  2. SCYX vs ICCM Comparison

SCYX vs ICCM Comparison

Compare SCYX & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCYX
  • ICCM
  • Stock Information
  • Founded
  • SCYX 1999
  • ICCM 2006
  • Country
  • SCYX United States
  • ICCM Israel
  • Employees
  • SCYX N/A
  • ICCM N/A
  • Industry
  • SCYX Biotechnology: Pharmaceutical Preparations
  • ICCM
  • Sector
  • SCYX Health Care
  • ICCM
  • Exchange
  • SCYX Nasdaq
  • ICCM Nasdaq
  • Market Cap
  • SCYX 50.3M
  • ICCM 45.5M
  • IPO Year
  • SCYX 2014
  • ICCM N/A
  • Fundamental
  • Price
  • SCYX $0.99
  • ICCM $1.11
  • Analyst Decision
  • SCYX Buy
  • ICCM Strong Buy
  • Analyst Count
  • SCYX 1
  • ICCM 2
  • Target Price
  • SCYX N/A
  • ICCM $2.70
  • AVG Volume (30 Days)
  • SCYX 212.6K
  • ICCM 505.6K
  • Earning Date
  • SCYX 11-06-2024
  • ICCM 11-26-2024
  • Dividend Yield
  • SCYX N/A
  • ICCM N/A
  • EPS Growth
  • SCYX N/A
  • ICCM N/A
  • EPS
  • SCYX N/A
  • ICCM N/A
  • Revenue
  • SCYX $8,566,000.00
  • ICCM $3,671,000.00
  • Revenue This Year
  • SCYX N/A
  • ICCM $10.03
  • Revenue Next Year
  • SCYX $405.82
  • ICCM $62.68
  • P/E Ratio
  • SCYX N/A
  • ICCM N/A
  • Revenue Growth
  • SCYX N/A
  • ICCM 26.02
  • 52 Week Low
  • SCYX $0.90
  • ICCM $0.48
  • 52 Week High
  • SCYX $3.07
  • ICCM $1.57
  • Technical
  • Relative Strength Index (RSI)
  • SCYX 30.44
  • ICCM 73.56
  • Support Level
  • SCYX $0.90
  • ICCM $0.79
  • Resistance Level
  • SCYX $1.25
  • ICCM $1.12
  • Average True Range (ATR)
  • SCYX 0.08
  • ICCM 0.08
  • MACD
  • SCYX -0.01
  • ICCM 0.02
  • Stochastic Oscillator
  • SCYX 23.54
  • ICCM 80.00

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About ICCM IceCure Medical Ltd.

Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.

Share on Social Networks: